Decibel Therapeutics

📍 Boston, United States👥 11 employees💰 Last funded Jan 2019
Biotechnology Research🌐 decibeltx.com
Website LinkedIn
Decibel Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, one of the largest areas of unmet need in medicine. Decibel has built a proprietary platform that integrates single-cell genomics and bioinformatic analyses, precision gene therapy technologies and expertise in inner ear biology. Decibel is leveraging its platform to advance gene therapies designed to selectively replace genes for the treatment of congenital, monogenic hearing loss and to regenerate inner ear hair cells for the treatment of acquired hearing and balance disorders. Decibel’s pipeline, including its lead gene therapy program, DB-OTO, to treat congenital, monogenic hearing loss, is designed to deliver on our vision of building a world of connection for people with hearing and balance disorders. Guidelines: https://bit.ly/3IzmNvU
1
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United Kingdom
1
Frequently asked questions
Who invested in Decibel Therapeutics?
Decibel Therapeutics has 1 investors on record on gritt.io.
When did Decibel Therapeutics last raise funding?
The most recent investment in Decibel Therapeutics recorded on gritt.io was in January 2019.
What industry is Decibel Therapeutics in?
Decibel Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Decibel Therapeutics based?
Decibel Therapeutics is headquartered in Boston, United States.